Clinical
Research & Trials
![patient-resources](https://www.firstcoastheart.com/hs-fs/hubfs/CVM_2022/Images/new-patient-information.png?width=722&height=537&name=new-patient-information.png)
Current Clinical Studies
CCM Therapy
CCM therapy is an investigational advanced treatment option currently available through clinical trials, using an implanted device designed to help improve heart function and manage heart failure symptoms.
Integra-D
This clinical trial investigates the safety and effectiveness of a new type of implantable defibrillator (ICD) called the Integra-D, a smaller and more efficient ICD designed to improve the quality of life for people with heart failure.
Impulse Dynamics
Our Research
Bay Area Cardiology physicians have been participating in clinical research since 1992.
Since then we have been involved in over 90 studies both nationally and internationally. Through patient-oriented research Bay Area Cardiology seeks to improve treatments and outcomes.
Bay Area Cardiology physicians have been participating in clinical research since 1992. Since then, we have been involved in over 120 studies both nationally and internationally. Through patient-oriented research Bay Area Cardiology seeks to improve treatments and outcomes.
Bay Area Cardiology is proud of its dedicated team of four full time professionals who are experienced at coordinating trials and maintaining a high standard of quality and performance.
Our experience with clinical trials includes registries, investigational medications, FDA post market approved drugs, coronary stents, peripheral stents, carotid stents, pacemakers, Bi-V and AICD devices.
We participate in both office and hospital based studies that cover a wide variety of cardiac and vascular medicine and treatments.
Our current enrolling clinical trials include treatment of:
- Hyperlipidemia (Both elevated LDL or LPa)
- Heart Failure
- Non-Valvular Atrial Fibrillation
- Peripheral Arterial Disease
- Acute MI (Heart attack)
- COPD
Examples of Our Clinical Studies:
![patient-information](https://www.firstcoastheart.com/hs-fs/hubfs/CVM_2022/Images/patient-information%20(2).png?width=72&height=74&name=patient-information%20(2).png)
ADAPTA (Medtronic)
A randomized trial to compare single-chamber atrial (AAl) and Dual-chamber (DDD) pacing in patients with Sick Sinus Syndrome
– Ranked #1 out of 100 sites
– PI: Dr. Mester
![patient-information](https://www.firstcoastheart.com/hs-fs/hubfs/CVM_2022/Images/patient-information%20(2).png?width=72&height=74&name=patient-information%20(2).png)
RELY (Boehringer Ingelheim)
– Ranked #9 out of 952 sites
– PI: Dr. Khant
![patient-information](https://www.firstcoastheart.com/hs-fs/hubfs/CVM_2022/Images/patient-information%20(2).png?width=72&height=74&name=patient-information%20(2).png)
RATE (St. Jude Medical)
– Ranked #5 out of 19 sites
– PI: Dr. Betzu
![patient-information](https://www.firstcoastheart.com/hs-fs/hubfs/CVM_2022/Images/patient-information%20(2).png?width=72&height=74&name=patient-information%20(2).png)
PREDETERMINE (NIHL)
– Ranked #6 out of 105 sites
– PI: Dr. Bugni
![patient-information](https://www.firstcoastheart.com/hs-fs/hubfs/CVM_2022/Images/patient-information%20(2).png?width=72&height=74&name=patient-information%20(2).png)
TRANSLATE (DCRI)
Treatment with ADP receptor iNhibitorS: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome
– Ranked #55 out of 233
– PI: Dr. Rodriguez
![](https://www.firstcoastheart.com/hs-fs/hubfs/CVM_2022/Images/patient-information%20(2).png?width=72&height=74&name=patient-information%20(2).png)
IMPROVE-IT (Merck/Schering Plough)
– Ranked #67 out of 359 sites
– PI: Dr. Betzu
![](https://www.firstcoastheart.com/hs-fs/hubfs/CVM_2022/Images/patient-information%20(2).png?width=72&height=74&name=patient-information%20(2).png)
CAMELLIA (Eisai)
– Ranked #3 out of 400 sites
– PI: Dr. Chokshi
![](https://www.firstcoastheart.com/hs-fs/hubfs/CVM_2022/Images/patient-information%20(2).png?width=72&height=74&name=patient-information%20(2).png)
Patient REVEAL (Merck/Oxford University)
– Ranked #61 out of 151 sites
– PI: Dr. Khan
![](https://www.firstcoastheart.com/hs-fs/hubfs/CVM_2022/Images/patient-information%20(2).png?width=72&height=74&name=patient-information%20(2).png)
PAH (Actelion)
Pulmonary Arterial Hypertension (PAH) Quality Enhancement Research Initiative (QuERI) Extension Program
– Ranked #22 out of 71 site
– PI: Dr. Dewhurst
![](https://www.firstcoastheart.com/hs-fs/hubfs/CVM_2022/Images/patient-information%20(2).png?width=72&height=74&name=patient-information%20(2).png)
ST SEGMENT (Medtronic)
– Ranked #4 out of 24 sites
– PI: Dr.Mester
![](https://www.firstcoastheart.com/hs-fs/hubfs/CVM_2022/Images/patient-information%20(2).png?width=72&height=74&name=patient-information%20(2).png)
1160.128 (Boehringer Ingelheim)
– Ranked #4 out of 26 sites
– PI: Dr. Khant
![](https://www.firstcoastheart.com/hs-fs/hubfs/CVM_2022/Images/patient-information%20(2).png?width=72&height=74&name=patient-information%20(2).png)
EFFECT-AF (Laser)
– Ranked #12 out of 54
– PI: Dr. Perzanowski
Interested in Participating? Contact Us Today to Learn More
![care_img2](https://www.firstcoastheart.com/hs-fs/hubfs/CVM_2022/Images/care_img2.png?width=665&height=860&name=care_img2.png)